Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin (MRG003) Added to Lenvatinib +/- Anti-PD-1 in Advanced Thyroid Cancer
NCT07874321Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of becotatug vedotin in thyroid cancer (2 cohorts), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective Response Rate at 18 weeks. Started Sep 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT07874321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07874321.